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Abstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for 
subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis 
(RA), juvenile RA, ankylosing spondylitis, and psoriatic arthritis. Etanercept binds to both TNFα 
and lymphotoxin and has quite a short mean half-life (70 hours). Numerous randomized clinical 
trials have demonstrated its efﬁ  cacy to improve signs and symptoms in early and established 
RA and other inﬂ  ammatory arthritis. Furthermore, etanercept has shown its ability to prevent 
radiographic progression and to improve health-related quality of life in patients with RA and 
psoriatic arthritis. A combination of etanercept plus methotrexate was more efﬁ  cacious than 
etanercept monotherapy in RA patients but there is currently no evidence that such rheumatic 
combination is better than monotherapy in other disorders. Etanercept was generally well toler-
ated both in controlled trials with withdrawal rates being similar to the comparator groups and 
in large observational studies. Infections and injection-site reactions were the most frequently 
reported events. Serious infections were slightly increased but the occurrence of tuberculosis 
seemed less frequent than with anti-TNF monoclonal antibodies (inﬂ  iximab and adalimumab). 
The beneﬁ  t-risk ratio of etanercept appeared to be very positive, and this drug has now emerged as 
a major therapy in patients with active inﬂ  ammatory arthritis. Furthermore, it is more frequently 
considered as an emerging and valuable option in patients with early disease.
Keywords: etanercept, TNF blockers, rheumatoid arthritis, juvenile rheumatoid arthritis, 
ankylosing spondylitis, psoriatic arthritis
Etanercept is a soluble dimeric fusion protein consisting of two copies of the extra-
cellular ligand binding portion of the human tumor necrosis factor (TNF) p75 receptor 
linked to the constant portion (Fc) of human immunoglobulin G1. Etanercept binds 
speciﬁ  cally to TNFα, a proinﬂ  ammatory cytokine, which plays a central role in the 
pathogenesis of different types of chronic inﬂ  ammatory arthritis by exerting a number 
of effects that contribute to synovial and enthesitis inﬂ  ammation and result in joint 
pathology (Choy and Panayi 2001; Culy and Keating 2002; Zhou 2005). Since it was 
licensed etanercept has dramatically improved the management and outcome of these 
chronic disorders as well as patient quality of life. Etanercept is currently approved 
both in Europe and in the US for subscutaneous use in the treatment of patients with 
moderate to severe active rheumatoid arthritis (RA), polyarticular juvenile RA, anky-
losing spondylitis (AS), psoratic arthritis (PsA), and plaque psoriasis. In this review 
we will focus only on the use of etanercept in rheumatic diseases.
Pharmacologic properties
The pharmacologic proﬁ  le of etanercept has been recently extensively reviewed (Culy 
and Keating 2002; Dhillon et al 2007). Etanercept binds to both TNFα and TNFβ 
(lymphotoxin), thereby blocking its interaction with cell surface receptors attenuating Biologics: Targets & Therapy 2008:2(2) 166
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or preventing TNF-mediated pro-inﬂ  ammatory effects and 
modulating the effect of other TNF-regulated molecules. The 
dimeric structure of etanercept means it can bind to two mol-
ecules of TNFα and is 50- to 1000-fold more efﬁ  cient than the 
monomeric soluble TNF receptor at neutralizing TNFα activity 
in vitro (Mohler et al 1993). Etanercept showed greater afﬁ  nity 
for TNF than inﬂ  iximab, a monoclonal antibody directed to 
TNFα (Davis et al 2002). In RA, etanercept reduced the level 
of pro-inﬂ  ammatory cytokines and other soluble mediators 
such as interleukin 6 (IL-6), IL-1, and matrix-metalloprotein-
ases, decreased the staining scores for CD3+ T cells, CD38+ 
plasma cells, and adhesion molecules, and decreased IL-1β 
expression and accumulation of chemokine receptor-positive 
T cells. These changes were correlated with improvement in 
disease activity (Culy and Keating 2002). Etanercept has also 
been shown to increase bone formation and decrease bone 
resorption, suggesting a joint protective effect (Soriolo et al 
2006). In several studies, etanercept did not have adverse 
effects on global immune function.
Anti-etanercept nonneutralizing antibodies were detected 
in some patients who where on etanercept therapy. However, 
their development was not correlated with blood level of 
the drug or with clinical efﬁ  cacy or adverse events. Auto-
antibodies have been detected in etanercept-treated patients 
but their frequency appeared to be lower than with inﬂ  iximab 
treatment and did not appear to be correlated with clinical 
symptoms such as lupus-like syndromes (Culy and Keating 
2002; Dhillon et al 2007).
The pharmacokinetic parameters in patients with RA are 
summarized in Table 1.
After subcutaneous injection, etanercept is slowly absorbed, 
with mean peak serum concentration reached between 53 and 
62 hours after repeated administration. The drug appears 
to be widely distributed, including into the synovium. It is 
slowly cleared from the body with an elimination half-life 
of 70 hours (30–300) in patients with RA. After binding to 
TNFα, the etanercept-TNF complex is probably metabolized 
by proteolytic processes, before recycling or elimination in 
the urine or bile (Zhou 2005). The steady-state concentration-
time proﬁ  le is similar for 50 mg once-weekly and 25 mg 
twice-weekly administration (Nestorov et al 2004). The 
pharmacokinetic properties of etanercept are not affected by 
gender, age or ethnicity, heart failure, or renal insufﬁ  ciency. 
They are also not altered with concomitant administration of 
methotrexate (MTX) or warfarin.
Therapeutic efﬁ  cacy in adult 
patients with rheumatoid arthritis
Therapeutic efﬁ  cacy of etanercept in RA has been reviewed 
in detail (Culy and Keating 2002; Dhillon et al 2007). This 
efﬁ  cacy has been evaluated by several well-designed trials 
both in late and early disease (Table 2). In addition, exten-
sions of these short-term trials and several large observational 
studies have evaluated its long-term efﬁ  cacy and its use in 
clinical practice. As it is recommended for the development 
of an efﬁ  cient drug in RA, etanercept has demonstrated clear 
efﬁ  cacy in clinical and radiographic measurement and on 
patient perspective (eg, quality of life measures). In most of 
the clinical trials, etanercept was administred twice weekly.
Efﬁ  cacy in patients with established RA
Efﬁ  cacy of etanercept was ﬁ  rst demonstrated in established 
RA, in patients who previously failed on traditional disease-
modifying anti-rheumatic drugs (DMARDs). More than 90% 
of these patients had  2 years’ disease duration. Eligible 
patients had active RA ( 6–10 swollen joints;  6–12 
tender joints) and were receiving a stable dosage of MTX, 
sulfasalazine, gold, or hydroxychloroquine for 4–6 weeks. 
When no treatment with DMARDs was permitted, a 4-week 
wash-out period was required.
Clinical response in monotherapy
In a 3-month phase II trial in patients for whom 4 DMARDs 
had failed, there was a dose-dependent improvement in 
all primary and efficacy variables in patients receiving 
0.25–16 mg twice weekly etanercept (Moreland et al 1997). 
At the higher dosage, 75% and 57% of the patients achieved 
ACR 20 and ACR 50 responses by 3 months versus 14% and 
7%, respectively, in the placebo group. In both this trial and 
a phase III trial (Moreland et al 1999), patients experienced 
a rapid response to etanercept with differences relative to 
placebo at week 2. In the phase III trial, a signiﬁ  cantly higher 
percentage of patients treated with etanercept (10 or 25 mg 
Table 1 Pharmacokinetic properties of etanercept in rheuma-
toid arthritis patients receiving multiple dose of subcutaneous 
etanercept
Parameter  25 mg biw  50 mg qw
 (EMEA)  (Nestorov  2004)
Cmax (mg/L)  2.6  2.4
Cmin (mg/L)  1.4  1.2
Tmax (h)  62  53
AUC (mg.h/L)  316  297
T ½ (h)  70–  100
Abbreviations: AUC, area under the concentration-time curve; biw, twice weekly; 
qw, once weekly; Cmax, maximum serum concentration; tmax, time to reach Cmax ; T ½, 
elimination half-life.Biologics: Targets & Therapy 2008:2(2) 167
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twice weekly) achieved ACR 20, 50, and 70 responses com-
pared with placebo both at 3 and 6 months, with a trend in 
favor of the 25 mg dosage. Most of the single variables of 
disease activity including swollen and tender joints counts, 
ESR, and CRP, were also improved compared with placebo. 
Long-term extension studies (up to 10 years) showed a sus-
tained clinical efﬁ  cacy (Dhillon et al 2007).
Health-related quality of life (HR-QOL), assessed by 
HAQ score or SF-36, was also improved in the etanercept 
groups compared with controls at 3 and 6 months but also 
in long-term extension studies (Moreland et al 1997, 1999, 
2006; Mathias et al 2000).
Clinical response in combination with methotrexate
Two main randomized, double-blind trials have demonstrated 
the clinical efﬁ  cacy of etanercept plus MTX combination in 
patients with late RA (Weinblatt et al 1999; Klareskog et al 
2004). In patients with inadequate response to MTX, com-
bination therapy was more effective than MTX plus placebo 
with 66% and 71% of ACR 20 responders in the etanercept 
plus MTX group respectively at 3 and 6 months versus 33 and 
27 % in the control group (Weinblatt et al 1999). The TEMPO 
trial (Klareskog et al 2004) was a 3-year randomized double-
study which compared etanercept monotherapy versus MTX 
therapy and etanercept plus MTX. At 6 months, the primary 
endpoint showed that the AUC ACRn in the combination 
group was greater compared with the MTX group (18.3% 
years vs 12.2% years; p  0.0001) with also a signiﬁ  cant 
difference between the etanercept and MTX groups (14.7% 
years vs 12.2; p = 0.0034). At 6 and 12 months, 83% and 
85%, respectively, of patients in the combination group 
achieved an ACR 20 response signiﬁ  cantly greater than in 
Table 2 Efﬁ  cacy of etanercept (ETN) in controlled trials versus methotrexate (MTX) or placebo (PBO) in patients with rheumatoid 
arthritis (RA)
Reference  Treatment  nr   Time point     Clinical response (% patients)
    patients  (months)  ACR   ACR   ACR   DAS 
       20  50  70  remission
Established RA             
  Moreland et al 1997  ETN* 0.25 mg/m2 180  3  33  9   
  ETN* 2 mg/m2     46 22  
  ETN* 16 mg/m2     75a 57a  
 PBO      14  7   
  Moreland et al 1999  ETN* 10 mg  234  6  51a 24a  
  ETN* 25 mg      59a 40a  
 PBO      11  5   
  Weinblatt et al 1999  ETN** + MTX  89  6  71c 39c 15b 
 MTX  + PBO      27  3  0 
  van Riel et al 2006  ETN** + MTX  314  4  67  40  18 
 ETN**      71  42  17 
  Kloreskog et al 2004  ETN** + MTX  682  12  85b,e 69d,f 43d,f 35d,f
 ETN**  + PBO      76  48  24  16
 MTX  + PBO      75  43  19  13
Early RA             
  Bathon et al 2006  ETN 10  632  12  60  34  16 
 ETN  25      72  49  25 
 MTX      65  43  22 
  Genovese et al 2002  ETN 10  512  24  61  35  19 
  (Extension study)  ETN 25      72b 49 29 
 MTX      59  42  24 
  Emery et al 2007  ETN + MTX  528  12  86c 71c 48c 50
 MTX      67  49  28  28
*Twice weekly
**ETN 25 mg twice weekly
ap  0.001 vs PBO
bp  0.05 vs MTX
cp  0.001 vs MTX
dp  0.0001 vs MTX
ep  0.05 vs ETN
fp  0.0001 vs ETNBiologics: Targets & Therapy 2008:2(2) 168
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the two monotherapy groups. Similar data were obtained 
for ACR 50 and 70 and DAS 28 score responses. At these 
evaluations, there was no difference in ACR responses 
between the two monotherapy groups. In addition, after 1 
year of treatment, the proportion of patients achieving DAS 
28 remission was signiﬁ  cantly higher in the combination 
group versus etanercept and MTX groups (35% vs 16% vs 
13% ; all p  0.0001). In the 2- and 3-year evaluations of the 
TEMPO trial, the combination of etanercept plus MTX was 
signiﬁ  cantly better than etanercept or MTX monotherapies on 
all measures of disease activity (van der Heijde et al 2006a, 
2007). Of the patients, 38.7%, 26.7%, and 23.6% achieved 
DAS 28 remission at 3 years respectively in the combination, 
the etanercept, and the MTX groups, respectively. In exten-
sion studies (3 years) efﬁ  cacy of etanercept plus MTX was 
sustained in the TEMPO trial and in patients with inadequate 
response to MTX (Kremer et al 2003).
The ADORE (ADd etanercept Or Replace MTX) trial 
was a 6-month open-label trial in patients with inadequate 
response to MTX ( 3 months) (van Riel et al 2006). Patients 
were randomized to switch MTX with etanercept or to add 
etanercept to MTX. By 6 months, there was a signiﬁ  cant 
improvement in both groups but no difference in any of the 
measurements of disease activity between the two groups.
HR-QOL measures at 12 months were better improved 
during the TEMPO trial in the etanercept plus MTX combina-
tion than in the monotherapy groups. In addition, more patients 
receiving combination therapy than both monotherapies had 
HAQ scores of  0.5 and achieved a clinically signiﬁ  cant 
improvement of HAQ disability (HAQ  0.22) (p  0.05) (van 
der Heijde et al 2006b). Patient satisfaction with medication 
was higher in the combination than in the MTX monotherapy 
group (p  0.0001) without signiﬁ  cant difference between 
combination and etanercept monotherapy (van der Heijde et al 
2006b). Similar trends on HR-QOL measures were observed 
at 2 and 3 years (van der Heijde et al 2006a, 2007).
Clinical response in combination 
with other DMARDs
A double-blind randomized study compared the effect of 
etanercept alone or in combination with sulfasalazine (SSZ) 
in patients with active RA and inadequate response to SSZ 
(Combe et al 2006). ACR 20 response rates at 24 weeks were 
signiﬁ  cantly higher for etanercept plus SSZ and etanercept 
monotherapy than SSZ alone (respectively 73.8 %, 74.0% 
vs 28%; p  0.01). The two etanercept groups did not dif-
fer. Similar trends were seen for ACR 50 and 70 responses 
at 24 weeks. A 2 years, the extension study showed similar 
results. No controlled trials evaluating the combination of 
etanercept and leﬂ  unomide are available; however, obser-
vational studies suggested that this combination could be 
an alternative option.
Radiography efﬁ  cacy
The TEMPO trial demonstrated that etanercept was effec-
tive in preventing radiographic progression of patients with 
established RA (Klareskog et al 2004; van der Heijde et al 
2006a, 2007). At 1 year, the van der Heijde modiﬁ  ed total 
Sharp Score (mTSS), and erosion and joint-space narrowing 
(JSN) scores had less progression in the etanercept plus MTX 
combination therapy than in the MTX monotherapy group 
(p  0.0001). There was also less progression for mTSS and 
JSN score in the combination group than in the etanercept 
monotherapy group (p  0.01) and less progression for mTSS 
and erosion score in the etanercept monotherapy group than 
in the MTX group (p = 0.046). The percentage of patients 
without radiographic progression was higher in the combi-
nation therapy group (80 %) than in the two monotherapy 
groups (p  0.005) and higher in the etanercept (68%) than 
in the MTX group (57 %; p = 0.02). Furthermore, at 2 and 3 
years, there was signiﬁ  cantly less structural progression in the 
combination group and less progression in patients receiving 
etanercept monotherapy than MTX monotherapy.
Efﬁ  cacy in patients with early rheumatoid 
arthritis
A double-blind randomized study evaluated etanercept 
monotherapy versus MTX in MTX-naïve patients with early 
RA at risk of disease progression (Bathon et al 2000). Etan-
ercept patients have a more rapid response to treatment than 
MTX group as evaluated by AUC ACRn (p  0.05). How-
ever, no statistical differences on ACR responses between 
the two groups were seen at 6- and 12-month evaluations. 
Extension study shows that the rate of ACR 20 responders 
was higher in etanercept 25 mg than in MTX group after 
2 years. Etanercept patients experienced more rapid improve-
ment in HR-QOL parameters as assessed by SF-36 and HAQ 
score, although there was no between-group difference from 
4 months onward (Bathon et al 2000).
The progression of the mTSS was lower at 6 months in 
the etanercept group but the difference with MTX-treated 
patients was not signiﬁ  cant at one year (Genovese et al 2002, 
2005). However, the mean change in erosion scores from 
baseline was smaller in etanercept than in MTX group both 
at 6 and 12 months. At 2 years, radiographic progression of 
both mTSS and erosion scores was reduced in the etanercept Biologics: Targets & Therapy 2008:2(2) 169
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versus MTX patients (p  0.02). The rate of patients with 
no progression was higher in the etanercept group at 1 and 
2 years.
The recent COMET study (Emery et al 2007) was designed 
to evaluate the DAS28 remission rate obtained after 1 and 2 
years of therapy in 528 patients with early RA (2 years 
disease duration) receiving etanercept plus MTX or MTX 
alone. At week 52, 50 % of patients on etanercept plus MTX 
achieved remission versus 28% on MTX alone (p 0.001). 
Low disease activity (DAS28  3.2) was achieved by 64% 
and 41% of patients in the etanercept plus MTX and MTX 
groups respectively (p  0.001). Percentage of patients who 
were ACR 20 (86% vs 67%), ACR 50 (71% vs 49%) and ACR 
70 (48% vs 28%) responders at week 52 were also statistically 
different between groups (p  0.001). The cumulative work 
days missed was also lower (15.0 vs 4.8) in the etanercept 
plus MTX group (p  0.05).
Therapeutic efﬁ  cacy in juvenile 
rheumatoid arthritis (JRA)
The efﬁ  cacy of etanercept monotherapy in reducing disease 
activity in young patients with JRA was demonstrated in a 
2-part trial which included a 3-month open trial then a 4-month 
double-blind, placebo-controlled phase (Lovell et al 2000). 
Sixty-nine children who had an inadequate response to MTX 
were enrolled; 40 of them had polyarticular arthritis and 22 had 
systemic arthritis. After 3 months of treatment with etanercept 
(0.4 mg/kg twice weekly), 51 patients (74%) and 25 (36%) 
experienced pediatric ACR 30 and 70 responses. All the patients 
who achieved the ACR 30 response were randomized to receive 
placebo or etanercept. After 4 months of therapy, disease ﬂ  are 
was observed in 81% in the placebo group compared with 
28% of those receiving etanercept (p = 0.003). The median 
time to ﬂ  are was longer in patients receiving etanercept (116 
vs 28 days; p  0.001). An open label extension trial showed 
a sustained efﬁ  cacy of etanercept after 2 and 4 years (Lovell 
et al 2003, 2006). Of the 58 patients who enrolled in the exten-
sion study, 34 patients received etanercept treatment for  4 
years and 32 of these showed complete efﬁ  cacy assessments. 
Furthermore, 94% and 78% achieved pediatric ACR 30 and 70 
respectively at the last study visit (Lovell et al 2006). Several 
other nonblind or observational studies supported the effect of 
etanercept in JRA (Culy and Keating 2002).
Therapeutic efﬁ  cacy in ankylosing 
spondylitis
Three randomized controlled trials have demonstrated strong 
efﬁ  cacy of etanercept monotherapy in patients suffering 
from AS (Davis et al 1995; Gorman et al 2002; Calin et al 
2004; Hoy and Scott 2007). These trials showed rapid 
and sustained improvement of spinal pain, global disease 
activity, and function as assessed by Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) and Bath 
Ankylosing Spondylitis Functional Index (BASFI) and 
HR QOL assessed by SF-36 scale after 24 and 102 weeks. 
Metrology index (BASMI) was also improved. The improve-
ment was usually seen within 2 weeks of therapy associated 
with a rapid decrease of CRP.
As an example in the 24 weeks study by Davis et al 
(1995), 277 patients were randomized to receive etanercept 
(25 mg twice weekly) or placebo. The rate of ASAS 20 
responders which was the primary endpoint was highly sig-
niﬁ  cantly different between the two groups (p  0.0001). The 
percentage of patients who improved the BASDAI score by 
more than 50 % were also signiﬁ  cantly in favor of etanercept 
as well as the rapid decrease of CRP level (Davis et al 1995; 
Gorman et al 2002; Calin et al 2004). After several months 
without etanercept, patients had had a disease ﬂ  are but rein-
troduction of the therapy was effective (Brandt et al 2005). 
Etanercept efﬁ  cacy was also suggested in undifferentiated 
spondylarthropathies (Brandt et al 2004).
In addition, the clinical efﬁ  cacy of etanercept was also 
supported by improvement of active spinal inﬂ  ammation as 
detected by MRI (Baraliakos et al 2005a). Finally, clinical 
and MRI efﬁ  cacy on enthesitis have also been shown in one 
study (Baraliakos et al 2005b). However, whether etaner-
cept treatment was able to control radiographic progression 
has not been demonstrated. Patients with early disease, or 
elevated CRP, or positive MRI inﬂ  ammation, or minimal 
structural abnormalities seemed to be more likely to respond 
than patients with late and advanced disease (Rudwaleit et al 
2004) but all patient types could beneﬁ  t from etanercept 
therapy. There is no indication that combination with MTX 
may provide additional beneﬁ  t.
Effectiveness of etanercept in the prevention and treatment 
of anterior uveitis has also been shown (Braun et al 2005) 
whereas effect on gut symptoms of inﬂ  ammatory bowel dis-
ease is unlikely at the tested dosages (Braun et al 2007).
Therapeutic efﬁ  cacy in psoriatic 
arthritis
Two double-blinded placebo-controlled trials evaluated 
the effect of etanercept (25 mg twice weekly) in patients 
suffering from PsA (Mease et al 2000; 2004; Woolacott 
et al 2006; Hoy and Scott 2007). In both trials, the 12 weeks 
(Mease et al 2000) or 24 weeks (Mease et al 2004) controlled Biologics: Targets & Therapy 2008:2(2) 170
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phase was followed by an open-label follow-up in which all 
patients received etanercept. PsA response criteria response 
was achieved by 87% and 70% of the patients at endpoint in 
the etanercept group versus 23% in the placebo group in both 
studies. ACR 20, 50 and 70 responses were also achieved 
by signiﬁ  cantly more patients in the etanercept group. There 
was no indication that concomitant MTX use provides an 
additional effect to etanercept alone. The effect on psoriasis 
was also in favor of etanercept based on PASI 75 and PASI 
50 at week 12 and 24. Radiographic assessment was available 
at 24 weeks and showed that disease progression as assessed 
by mTSS was signiﬁ  cantly lower in patients treated with 
etanercept compared with the placebo group (Mease et al 
2004) and at 1 year, the mean annualized rate (–0.03) of 
radiographic progression indicated no signiﬁ  cant progression 
of joint erosions for all etanercept patients.
Safety of etanercept in rheumatic 
disorders
Etanercept was generally well tolerated in the different 
clinical trials that were reported above in the efﬁ  cacy sec-
tions whatever the rheumatic diseases where it was evalu-
ated. Safety data are also supported by long term extension 
studies, by several national registries both in EU and in the 
US (Setoguchi et al 2006; Strangfeld and Listing 2006; 
Askling et al 20007; Carmona et al 2007; Dixon et al 2007a; 
Jacobsson et al 2007; Michaud and Wolfe 2007; Schneeweiss 
et al 2007; Wolfe and Michaud 2007) and by reports from 
the US and European agencies. Furthermore, more than 1 
million patient-years have been exposed to etanercept all 
over the world.
In the controlled trials, the rate of discontinuation linked 
to treatment-related adverse events was not signiﬁ  cantly 
increased in patients receiving etanercept. Severity of adverse 
events was generally mild to moderate. The most frequent 
adverse events reported in patients receiving etanercept were 
infections and injection-site reactions. Addition of metho-
trexate or other DMARD did not seem to increase the rate of 
side-effects related to etanercept. By contact, the combination 
with other biological therapy such as anakinra (Genovese 
et al 2004) or abatacept (Weinblatt et al 2006) increased the 
incidence of infections and is not recommended.
Injection-site reactions
The incidence of injection-site reactions was higher in etan-
ercept treated patients than in control groups. They were 
usually mild including pain, itching, and erythema and gener-
ally did not require drug discontinuation. The frequency of 
these reactions varied widely across the studies and usually 
occurred during the ﬁ  rst weeks of therapy.
Infections
Infections were the most frequently reported adverse events 
in the clinical trials but without significant differences 
between etanercept and control groups. Serious infections, 
by contrast, were more frequently reported both in controlled 
trials and in observational studies in patients treated with 
etanercept with an odd-ratio around two compared with 
patients treated with nonbiologic anti-rheumatic therapies 
such as methotrexate or other DMARDs. There is no evi-
dence that the frequency of serious infections with etanercept 
could be different to that observed with other TNF blockers. 
Consistent data from observational studies suggested that 
the rate of serious infections could be mainly increased dur-
ing the ﬁ  rst 6 months of therapy (Askling et al 2007; Dixon 
et al 2007a). Upper respiratory tract infections, sinusitis, 
urinary tract infections, and soft tissues infections were the 
most commonly reported infections. In open-extension trials 
of  8.2 years’ duration, the incidence of serious infections 
was 2.0–4.2 events/100 patient-years (Kremer et al 2003; 
Moreland et al 2006; Genovese et al 2005). Rare but severe 
opportunistic infections including tuberculosis have also been 
observed. Similarly to other TNF blockers, the occurrence 
of tuberculosis appeared to be due to reactivation of latent 
tuberculosis. However, there have been more reported cases 
of tuberculosis in individuals treated with inﬂ  iximab and 
adalimumab than using etanercept and there are now con-
sistent data suggesting that the risk of reactivation of latent 
tuberculosis is signiﬁ  cantly lower with etanercept than with 
monoclonal antibodies (Furst et al 2006, 2007; Tubach et al 
2007). Screening of patients and antibioprophylaxis before 
starting anti-TNF therapy has reduced the risk of activating 
tuberculosis (Carmona et al 2005) and is recommended 
with the three drugs (Furst et al 2007). Recent data from the 
German registry have also suggested that the occurrence 
of herpes virus and herpes zoster infections may be lower 
in patients using etanercept than adalimumab or inﬂ  iximab 
(Strangfeld et al 2007).
In hepatitis C, observational studies and one controlled 
trial showed that etanercept did not have an effect on viral 
load and there was no increase in incidence of adverse 
effects (Khanna et al 2003). In hepatitis B, patients treated 
with all three anti-TNF agents have experienced increased 
symptoms and worsening of viral load (Furst et al 2007). 
Consequently, TNF blockers should not be used in patients 
with known hepatitis B infection; in hepatitis C, etanercept Biologics: Targets & Therapy 2008:2(2) 171
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may be prescribed but with tight control in patients with viral 
load (Furst et al 2007).
Etanercept does not signiﬁ  cantly inﬂ  uence the develop-
ment of protective antibodies after vaccination (Kapetanovic 
et al 2007). Vaccination with live attenuated vaccines is 
contra-indicated as with other immunosuppressive medica-
tions.
Malignancies
There are still conﬂ  icting data about whether or not there is 
an increased risk for lymphoma and solid tumors with anti-
TNF agents. Several large observational databases and a case 
control study did not demonstrate an increased incidence 
of malignancies in patients receiving anti-TNF therapies 
(Setoguchi et al 2006; Dhillon et al 2007; Jacobsson et al 
2007; Wolfe and Michaud 2007; Furst et al 2007). Only the 
risk of nonmelanoma skin cancer might be increased (Furst 
et al 2007; Wolfe and Michaud 2007).
The incidence of malignancies that has been reported in 
etanercept recipients during clinical trials and post-marketing 
surveillance was not different to that expected in the general 
population (EMEA; Okada and Siegel 2006). However, 
vigilance with respect to the occurrence of malignancies 
including recurrence of solid tumors remains warranted in 
patients using etanercept and other TNF blockers.
Other adverse events
A low percentage of patients receiving etanercept may 
develop autoantibodies including anti-nuclear antibodies, 
anti-double-stranded DNA antibodies, and anti-cardiolipin 
antibodies; however, there is no evidence that these patients 
are at signiﬁ  cantly increased risk for the development of 
clinical symptoms (Dhillon et al 2007; Furst et al 2007). 
Rare cases of drug-induced lupus have been observed with 
the three anti-TNF agents (Furst et al 2007).
Around 5% of patients developed nonneutralizing anti-
etanercept antibodies which did not seemed to affect the efﬁ  -
cacy and the safety of the drug (EMEA). Allergic reactions 
including angio-edema and urticaria have been described 
in etanercept-treated patients. Rare cases of central nervous 
system demyelinating disorders or pancytopenia or aplastic 
anemia have been also reported. Worsening of congestive 
heart failure (CHF) has been associated with anti-TNF 
therapy, mainly in patients treated with high dose inﬂ  iximab, 
but there is presently no evidence that etanercept 50 mg/week 
increases the incidence of CHF or CHF mortality (Khanna 
et al 2004). There is no evidence that etanercept may have a 
negative effect during pregnancy; however, there is currently 
insufﬁ  cient information to safely counsel the continuation of 
any TNF blocker during pregnancy (Furst et al 2007).
Conclusion
Subcutaneous etanercept (50 mg once weekly or 25 mg 
twice weekly) has emerged as a major new therapy in a large 
spectrum of inﬂ  ammatory rheumatic disorders including 
rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing 
spondylitis, and psoriatic arthritis. Etanercept has demon-
strated signiﬁ  cant clinical efﬁ  cacy compared to control in 
these diseases and has shown its ability to stop or prevent 
radiographic progression of joint damage in patients with 
rheumatoid arthritis or psoriatic arthritis. Combination of 
etanercept plus methotrexate has shown a greater efﬁ  cacy 
than etanercept monotherapy in rheumatoid arthritis patients 
but there is no clear evidence that adding etanercept is more 
efﬁ  cient than switching to etanercept in patients with inad-
equate response to methotrexate. Etanercept is generally 
well tolerated and the safety of the drug has been reassured 
by data from clinical trials, long-term observational studies 
and post-marketing surveillance with almost 10 years of use 
in clinical practice.
Etanercept has shown some advantages to other 
TNF blockers including safety (tuberculosis, herpes zos-
ter), absence of signiﬁ  cant development of neutralizing 
antibodies, and some better evidence of efﬁ  cacy when used 
in monotherapy in patients with rheumatoid arthritis.
Etanercept is usually recommended to be used as a second 
line agent in patients with active inﬂ  ammatory arthritis and 
inadequate response to standard therapy. However, etanercept 
can be proposed as ﬁ  rst DMARD in combination with metho-
trexate in patients with early rheumatoid arthritis with very 
active disease and/or high risk of developing severe disease 
(Combe 2007; Combe et al 2007; Fautrel et al 2007; Furst et al 
2007). In patients with early rheumatoid arthritis, etanercept 
in combination with methotrexate has demonstrated a high 
rate of responders and a high rate of disease remission and is 
now considered as an emerging option in these patients.
Recent evidence has suggested that etanercept and other 
TNF blockers may reduce the risk of cardiovascular disease, 
mortality (Jacobsson et al 2007 Dixon et al 2007b), and the 
need for joint surgery in patients with rheumatoid arthritis and 
may also be cost-effective from a societal perspective, but 
further research is needed to conﬁ  rm these important issues.
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